FAP and lung carcinoma: Preclinical investigations have explored various approaches, including FAP deletion through LacZ knock-in or Diphtheria toxin targeting FAP+ CAFs in lung cancer, colon cancer, and pancreatic cancer xenograft models, demonstrating notable antitumor efficacy [251, 252].